Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.80 |
| ▸ | ROCK1 | Q13464 | 14/20 | 0.80 |
| ▸ | ARHGDIA | P52565 | 4/20 | 0.80 |
| ▸ | CCR2 | P41597 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974051 | 0.89 | ROCK2 (1.00) | ROCK2ROCK1ARHGDIACCR2 | |
| SCHEMBL1716535 | 0.84 | ROCK2 (0.79) | ROCK2ROCK1CCR2 | |
| SCHEMBL1974858 | 0.83 | ROCK2 (1.00) | ROCK2ROCK1ARHGDIACCR2 | |
| SCHEMBL1974291 | 0.83 | ROCK2 (1.00) | ROCK2ROCK1ARHGDIA | |
| SCHEMBL5415148 | 0.81 | ROCK2 (0.81) | ROCK2ROCK1ARHGDIACCR2 | |
| SCHEMBL5423824 | 0.80 | ROCK2 (0.70) | ROCK2ROCK1ARHGDIACCR2 | |
| SCHEMBL5412656 | 0.80 | ROCK2 (0.73) | ROCK2ROCK1ARHGDIACCR2 | |
| SCHEMBL5419608 | 0.79 | ROCK2 (0.71) | ROCK2ROCK1ARHGDIACCR2 | |
| SCHEMBL5413166 | 0.78 | ROCK2 (0.70) | ROCK2ROCK1ARHGDIACCR2 | |
| SCHEMBL5404303 | 0.78 | ROCK2 (0.70) | ROCK2ROCK1ARHGDIACCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476295-B2 | Bridged bicyclic RHO kinase inhibitor compounds, composition and use | Inspire (US) | 2013-07-02 | — | — | US | claimed |
| US-20110144150-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | claimed |
| US-8835457-B2 | Bridged bicyclic RHO kinase inhibitor compounds, compositions and use | MERCK SHARP & DOHME CORP. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835457-B2 | Bridged bicyclic RHO kinase inhibitor compounds, compositions and use | MERCK SHARP & DOHME CORP. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130281485-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND USE | MERCK SHARP & DOHME LLC | 2013-10-24 | — | — | US | disclosed |
| US-20130281485-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND USE | MERCK SHARP & DOHME LLC | 2013-10-24 | — | — | US | disclosed |
| US-8476295-B2 | Bridged bicyclic RHO kinase inhibitor compounds, composition and use | Inspire (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476295-B2 | Bridged bicyclic RHO kinase inhibitor compounds, composition and use | Inspire (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110144150-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110144150-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281485-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND USE | ROCK1, RHOA, ROCK2 | ROCK2 3/4885ROCK1 1/4885ARHGDIA 6/4885 |
| US-20110144150-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | ROCK2 3/4885ROCK1 1/4885ARHGDIA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.